Microscopic-observation drug-susceptibility assay for the diagnosis of TB

New England Journal of Medicine

Volumn 355, Issue 15, 2006, Pages 1539-1550

  Moore, David A J ^a,b,c,h   Evans, Carlton A W ^a,b,c,h   Gilman, Robert H ^b,c,h   Caviedes, Luz ^c   Coronel, Jorge ^c   Vivar, Aldo ^d   Sanchez, Eduardo ^e   Piñedo, Yvette ^d   Saravia, Juan Carlos ^f   Salazar, Cayo ^g   Oberhelman, Richard ⁱ   Hollm Delgado, Maria Graciela ^b   LaChira, Doris ^g   Escombe, A Roderick ^a,b,c   Friedland, Jon S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d HOSPITAL NACIONAL ARZOBISPO LOAYZA   (Peru)

^e Hospital Nacional Hipólito Unanue   (Peru)

^f MINISTERIO DE SALUD   (Peru)

^g Direccion de Salud IV Lima Este   (Peru)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; TUBERCULOSIS;

ADULT; BACTERIOLOGICAL TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33749649080     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa055524     Document Type: Article

References (42)

1. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization, 2006:1-242. (Accessed September 15, 2006, at http://www.who.int/tb/publications/global_report/2006/en/index.html.)
2. The global plan to stop TB, 2006-2015 Geneva: Stop TB Partnership and World Health Organization, 2006:1-172. (Accessed September 15, 2006, at http://www.stoptb.org/globalplan.)
3. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-45.
4. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004;8:52-8.
5. Dowdy DW, Chaisson RE, Moulton LH, Dorman SE. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 2006;20:751-62.
6. Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J Clin Microbiol 2000;38:1203-8.
7. Moore DA, Mendoza D, Gilman RH, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol 2004;42:4432-7.
8. Small PM, Perkins MD. More rigour needed in trials of new diagnostic agents for tuberculosis. Lancet 2000;356:1048-9.
9. Suffys P, Palomino JC, Cardoso Leao S, et al. Evaluation of the polymerase chain reaction for the detection of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2000;4:179-83.
10. Tessema TA, Hamasur B, Bjun G, Svenson S, Bjorvatn B. Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. Scand J Infect Dis 2001;33:279-84.
11. Tsubura E, Yamanaka M, Sakatani M, Takashima T, Maekura R, Nakatani K. A cooperative clinical study on the evaluation of an antibody detection kit (MycoDot test) for mycobacterial infections. Kekkaku 1997;72:611-5. (In Japanese.)
12. Somi GR, O'Brien RJ, Mfinanga GS, Ipuge YA. Evaluation of the MycoDot test in patients with suspected tuberculosis in a field setting in Tanzania. Int J Tuberc Lung Dis 1999;3:231-8.
13. Cole RA, Lu HM, Shi YZ, Wang J, De-Hua T, Zhou AT. Clinical evaluation of rapid immunochromatographic assay based on the 38 kDa antigen of Mycobacterium tuberculosis on patients with pulmonary tuberculosis in China. Tuber Lung Dis 1996;77:363-8.
14. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research: getting better but still not good. JAMA 1995;274:645-51.
15. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-30.
16. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Intern Med 2003;138:40-4.
17. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-W12.
18. Begg CB. Biases in the assessment of diagnostic tests. Stat Med 1987;6:411-23.
19. Walsh A, McNerney R. Guidelines for establishing trials of new tests to diagnose tuberculosis in endemic countries. Int J Tuberc Lung Dis 2004;8:609-13.
20. Perkins MD, Kritski AL. Diagnostic testing in the control of tuberculosis. Bull World Health Organ 2002;80:512-3.
21. Laboratory services in TB control. Parts I, II, and III. Geneva: World Health Organization, 1998. (Publication no. WHO/tb/98.258.)
22. Park WG, Bishai WR, Chaisson RE, Dorman SE. Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol 2002;40:4750-2.
23. Del Portillo P, Thomas MC, Martinez E, et al. Multiprimer PCR system for differential identification of mycobacteria in clinical samples. J Clin Microbiol 1996;34:324-8.
24. Bemer P, Bodmer T, Munzinger J, Perrin M, Vincent V, Drugeon H. Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2004;42:1030-4.
25. Barreto AM, Araujo JB, de Melo Medeiros RF, de Souza Caldas PC. Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system. Mem Inst Oswaldo Cruz 2003;98:827-30.
26. Yew WW, Tong SC, Lui KS, Leung SK, Chau CH, Wang EP. Comparison of MB/BacT system and agar proportion method in drug susceptibility testing of Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2001;39:229-32.
27. Tortoli E, Mattei R, Savarino A, Bartolini L, Beer J. Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems. Diagn Microbiol Infect Dis 2000;38:83-6.
28. Diaz-Infantes MS, Ruiz-Serrano MJ, Martinez-Sanchez L, Ortega A, Bouza E. Evaluation of the MB/BacT mycobacterium detection system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2000;38:1988-9.
29. Brunello F, Fontana R. Reliability of the MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to antituberculous drugs. J Clin Microbiol 2000;38:872-3.
30. Kumar M, Khan IA, Verma V, Qazi GN. Microplate nitrate reductase assay versus Alamar Blue assay for MIC determination of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2005;9:939-41.
31. Reis RS, Neves I Jr, Lourenco SL, Fonseca LS, Lourenco MC. Comparison of flow cytometric and Alamar Blue tests with the proportional method for testing susceptibility of Mycobacterium tuberculosis to rifampin and isoniazid. J Clin Microbiol 2004;42:2247-8.
32. Sungkanuparph S, Pracharktam R, Thakkinstian A, Buabut B, Kiatatchasai W. Correlation between susceptibility of Mycobacterium tuberculosis by microtiter plate Alamar Blue assay and clinical outcomes. J Med Assoc Thai 2002;85:820-4.
33. Pracharktam R, Angkananukool K, Vibhagool A. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar Blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand. J Med Assoc Thai 2001;84:1241-5.
34. Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998;36:362-6.
35. Collins L, Franzblau SG. Microplate Alamar Blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997;41:1004-9.
36. Moore DA, Caviedes L, Gilman RH, et al. Infrequent MODS TB culture cross-contamination in a high-burden resource-poor setting. Diagn Microbiol Infect Dis 2006;56:35-43.
37. Oberhelman RA, Soto-Castellares G, Caviedes L, et al. Improved recovery of Mycobacterium tuberculosis from children using the Microscopic Observation Drug Susceptibility (MODS) method. Pediatrics 2006;118:e100-e106.
38. Perkins MD. New diagnostic tools for tuberculosis. Int J Tuberc Lung Dis 2000;4:Suppl 2:S182-S188.
39. Madison B, Robinson-Dunn B, George I, et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002;40:3976-9.
40. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
41. Shin S, Furin J, Bayona J, Mate K, Kim JY, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004;59:1529-39.
42. Tuberculosis bacteriology - priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005;9:355-61.